Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is the most common chromosomal abnormal heart disease. The pathophysiological mechanism of HCM is complex. Several studies have suggested that the level of Soluble ST2 (sST2) may be a biomarker of chronic systolic heart failure, however, the role of sST2 in HCM remains unclear. So we performed this study to analyze the role of Soluble ST2 (sST2), and its correlations with clinical prognosis of patients with hypertrophic cardiomyopathy (HCM) undergoing ventricular septal myectomy.Methods: HCM patients who underwent modified Morrow surgery in our hospital during June 2016-June 2018 were included. We divided the patients into different groups stratified by sST2 and Gal-3 level. Besides, we included volunteers without heart disease for medical examination as normal controls. Biochemical analyses were conducted to identify the biomarkers difference. The predictive value of sST2 and Gal-3 on all-cause mortality was evaluated with Cox regression analysis.Results: A total of 125 HCM patients were included in this present study. The sST2 and Gal-3 levels in HCM patients were significantly higher than that in control group (all P<0.001); there were significant differences in the incidence of all-cause mortality for HCM patients stratified by the sST2 and Gal-3 level;

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

“…Inhibition of the Gal-3 pathway, which is currently one of the most promising novels therapeutic targets for managing myocardial fibrosis, may prevent cardiac remodeling and dysfunction In the preclinical study ( 54 ). Furthermore, previous clinical research has shown that Gal-3 as a biomarker is correlated with CV disease risk stratification ( 55 ) or adverse prognosis ( 52 , 56 ). In the field of HF, Gal-3 has proven to provide additive diagnostic and prognostic value ( 57 , 58 ) and was recommended as a novel biological indicator for the risk stratification of HF at the 2013 American College of Cardiology Foundation (ACCF) /American Heart Association (AHA) ( 59 ).…”

“…It is primarily secreted by activated macrophages during myocardial stress and stimulates fibroblasts to deposit collagen into the extracellular matrix ( 50 ), initiating the pro-fibrotic progression of the myocardium ( 51 ). Song et al ( 52 ) and Yakar Tuluce et al ( 53 ) found a connection between Gal-3 levels and the degree of LV hypertrophy in individuals with hypertrophic cardiomyopathy (HCM). Inhibition of the Gal-3 pathway, which is currently one of the most promising novels therapeutic targets for managing myocardial fibrosis, may prevent cardiac remodeling and dysfunction In the preclinical study ( 54 ).…”